Pku Healthcare Corp.Ltd(000788) 415 announcement: Recently, the company received the notice of approval of drug supplement application approved and issued by the State Drug Administration. The declared “compound sulfamethoxazole tablets (dosage form: tablets; specification: sulfamethoxazole 0.4g, trimethoprim 80mg; registered classification: chemicals)” has passed the evaluation of the quality and efficacy consistency of generic drugs.
The data show that compound sulfamethoxazole is a compound preparation of sulfamethoxazole (SMZ) and trimethoprim (TMP), which is the representative of clinical sulfonamides at present. The drug is mainly used for urinary tract infection caused by sensitive strains of Escherichia coli, Klebsiella, enterobacter, Proteus mirabilis, Proteus vulgaris and Morganella.
Pku Healthcare Corp.Ltd(000788) said that the company’s compound sulfamethoxazole tablets passed the generic drug quality and efficacy consistency evaluation, which is the recognition of the company’s comprehensive R & D and production capacity and product quality by the national drug regulatory department. At the same time, it also accumulated valuable experience for the company’s follow-up generic drug consistency evaluation, which is of positive significance to the improvement of the company’s R & D capacity.
